Prostate-specific antigen density as a powerful predictor of extracapsular extension and positive surgical margin in radical prostatectomy patients with prostate-specific antigen levels of less than 10ng/ml

Korean Journal of Urology

Volumn 52, Issue 12, 2011, Pages 809-814

  Chang, Jin Seok ^a   Choi, Hoon ^a   Chang, Young Seop ^a   Kim, Jin Bum ^a   Oh, Mi Mi ^b   Moon, Du Geon ^b   Bae, Jae Hyun ^b   Cheon, Jun ^b  

^a Department of Urology   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

Extracapsular extension; Positive surgical margin; Prostatectomy; PSAD

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; DIGITAL RECTAL EXAMINATION; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE; PROSTATE CANCER; PROSTATECTOMY; RECEIVER OPERATING CHARACTERISTIC; SURGICAL PATIENT;

EID: 84455194592     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2011.52.12.809     Document Type: Article

References (29)

1. Hara I, Miyake H, Hara S, Yamanaka N, Ono Y, Eto H, et al. Value of the serum prostate-specific antigen-alpha 1-antichymotrypsin complex and its density as a predictor for the extent of prostate cancer. BJU Int 2001;88:53-7.
2. Smith JA Jr, Scardino PT, Resnick MI, Hernandez AD, Rose SC, Egger MJ. Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: results of a prospective, multi-institutional trial. J Urol 1997;157:902-6.
3. Zheng XY, Xie LP, Wang YY, Ding W, Yang K, Shen HF, et al. The use of prostate specific antigen (PSA) density in detecting prostate cancer in Chinese men with PSA levels of 4-10 ng/mL. J Cancer Res Clin Oncol 2008;134:1207-10.
4. Rietbergen JB, Hoedemaeker RF, Kruger AE, Kirkel WJ, Schröder FH. The changing pattern of prostate cancer at the time of diagnosis: characteristics of screen detected prostate cancer in a population based screening study. J Urol 1999;161:1192-8.
5. Shinohara K, Wolf JS Jr, Narayan P, Carroll PR. Comparison of prostate specific antigen with prostate specific antigen density for 3 clinical applications. J Urol 1994;152:120-3.
6. Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J UroI 1990;143:747-52.
7. Graefen M, Haese A, Pichlmeier U, Hammerer PG, Noldus J, Butz K, et al. A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy. J Urol 2001;165:857-63.
8. Ohori M, Kattan MW, Koh H, Maru N, Slawin KM, Shariat S, et al. Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol 2004;171:1844-9.
9. Choi H, Ko YH, Kang SG, Kang SH, Park HS, Cheon J, et al. Biopsy related prostate status does not affect on the clinicopathological outcome of robotic assisted laparoscopic radical prostatectomy. Cancer Res Treat 2009;41:205-10.
10. Gancarczyk KJ, Wu H, McLeod DG, Kane C, Kusuda L, Lance R, et al. Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms. Urology 2003;61:589-95.
11. Ishida M, Nakashima J, Hashiguchi A, Mizuno R, Shinoda K, Kikuchi E, et al. Are predictive models for cancer volume clinically useful in localized prostate cancer? Int J Urol 2009;16:936-40.
12. Lee JT, Lee S, Yun CJ, Jeon BJ, Kim JM, Ha HK, et al. Prediction of perineural invasion and its prognostic value in patients with prostate cancer. Korean J Urol 2010;51:745-51.
13. Nakanishi H, Troncoso P, Babaian RJ. Prediction of extraprostatic extension in men with biopsy Gleason score of 8 or greater. J Urol 2008;180:2441-5.
14. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tomaszewski JE, et al. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol 1995;154:131-8.
15. Mian BM, Troncoso P, Okihara K, Bhadkamkar V, Johnston D, Reyes AO, et al. Outcome of patients with Gleason score 8 or higher prostate cancer following radical prostatectomy alone. J Urol 2002;167:1675-80.
16. Kattan MW, Stapleton AM, Wheeler TM, Scardino PT. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer 1997;79:528-37.
17. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE. Combination of prostate specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277: 1445-51.
18. Graefen M, Haese A, Pichlmeier U, Hammerer PG, Noldus J, Butz K, et al. A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy. J Urol 2001;165:857-63.
19. Naya Y, Slaton JW, Troncoso P, Okihara K, Babaian RJ. Tumor length and location of cancer on biopsy predict for side specific extraprostatic cancer extension. J Urol 2004;171:1093-7.
20. Tsuzuki T, Hernandez DJ, Aydin H, Trock B, Walsh PC, Epstein JI. Prediction of extraprostatic extension in the neurovascular bundle based on prostate needle biopsy pathology, serum prostate specific antigen and digital rectal examination. J Urol 2005;173: 450-3.
21. Cookson MS, Fleshner NE, Soloway SM, Fair WR. Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications. J Urol 1997;157: 559-62.
22. Wang X, Brannigank RE, Rademaker AW, McVary KT, Oyasu R. One core positive prostate biopsy is a poor predictor of cancer volume in the radical prostatectomy specimen. J Urol 1997;158: 1431-5.
23. Cheng L, Slezak J, Bergstralh EJ, Myers RP, Zincke H, Bostwick DG. Preoperative prediction of surgical margin status in patients with prostate cancer treated by radical prostatectomy. J Clin Oncol 2000;18:2862-8.
24. Gancarczyk KJ, Wu H, McLeod DG, Kane C, Kusuda L, Lance R, et al. Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms. Urology 2003;61:589-95.
25. Noguchi M, Stamey TA, McNeal JE, Yemoto CM. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer. J Urol 2001;166:104-9.
26. Noldus J, Stamey TA. Limitations of serum prostate specific antigen in predicting peripheral and transition zone cancer volumes as measured by correlation coefficients. J Urol 1996;155:232-7.
27. Seaman EK, Whang IS, Cooner W, Olsson CA, Benson MC. Predictive value of prostate-specific antigen density for the presence of micrometastatic carcinoma of the prostate. Urology 1994;43:645-8.
28. Taneja SS, Hsu EI, Cheli CD, Walden P, Bartsch G, Horninger W, et al. Complexed prostate-specific antigen as a staging tool: results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosis. Urology 2002;60(4 Suppl 1):10-7.
29. Naya Y, Fritsche HA, Cheli CD, Stamey TA, Bartsch G, Brawer MK, et al. Volume indexes of total, free, and complexed prostate-specific antigen enhance prediction of extraprostatic disease extension in men with nonpalpable prostate cancer. Urology 2003;62:1058-62.